BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31953433)

  • 1. Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
    Bjarnadottir O; Feldt M; Inasu M; Bendahl PO; Elebro K; Kimbung S; Borgquist S
    Sci Rep; 2020 Jan; 10(1):558. PubMed ID: 31953433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
    Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
    Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
    Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
    Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
    Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
    Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
    Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
    Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
    Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
    Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
    Gustbée E; Tryggvadottir H; Markkula A; Simonsson M; Nodin B; Jirström K; Rose C; Ingvar C; Borgquist S; Jernström H
    BMC Clin Pathol; 2015; 15():8. PubMed ID: 26109908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of HMGCR expression in combination therapy of simvastatin and FAC treated locally advanced breast cancer patients.
    Yulian ED; Siregar NC; Sudijono B; Hwei LRY
    Breast Dis; 2023; 42(1):73-83. PubMed ID: 36938720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan.
    Watanabe Y; Suzuki S; Nishimura H; Murata KY; Kurashige T; Ikawa M; Asahi M; Konishi H; Mitsuma S; Kawabata S; Suzuki N; Nishino I
    Medicine (Baltimore); 2015 Jan; 94(4):e416. PubMed ID: 25634171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.
    Marks MP; Giménez CA; Isaja L; Vera MB; Borzone FR; Pereyra-Bonnet F; Romorini L; Videla-Richardson GA; Chasseing NA; Calvo JC; Vellón L
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):106. PubMed ID: 38418798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.
    Mammen AL; Pak K; Williams EK; Brisson D; Coresh J; Selvin E; Gaudet D
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):269-72. PubMed ID: 21972203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
    Gray RT; Loughrey MB; Bankhead P; Cardwell CR; McQuaid S; O'Neill RF; Arthur K; Bingham V; McGready C; Gavin AT; James JA; Hamilton PW; Salto-Tellez M; Murray LJ; Coleman HG
    Br J Cancer; 2017 Jun; 116(12):1652-1659. PubMed ID: 28524155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
    Bengtsson E; Nerjovaj P; Wangefjord S; Nodin B; Eberhard J; Uhlén M; Borgquist S; Jirström K
    Diagn Pathol; 2014 Apr; 9():78. PubMed ID: 24708688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase.
    Li MX; Yang Y; Zhao Q; Wu Y; Song L; Yang H; He M; Gao H; Song BL; Luo J; Rao Y
    J Med Chem; 2020 May; 63(9):4908-4928. PubMed ID: 32321253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and myositis: the role of anti-HMGCR antibodies.
    Selva-O'Callaghan A; Alvarado-Cardenas M; Marin A; Pinal-Fernandez I
    Expert Rev Clin Immunol; 2015; 11(12):1277-9. PubMed ID: 26492593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and statin sensitivity.
    Jawaid S; Gertz M; Corsino C; Cheung J; Seidle H; Couch RD
    Indian J Biochem Biophys; 2010 Dec; 47(6):331-9. PubMed ID: 21355415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study.
    Musset L; Allenbach Y; Benveniste O; Boyer O; Bossuyt X; Bentow C; Phillips J; Mammen A; Van Damme P; Westhovens R; Ghirardello A; Doria A; Choi MY; Fritzler MJ; Schmeling H; Muro Y; García-De La Torre I; Ortiz-Villalvazo MA; Bizzaro N; Infantino M; Imbastaro T; Peng Q; Wang G; Vencovský J; Klein M; Krystufkova O; Franceschini F; Fredi M; Hue S; Belmondo T; Danko K; Mahler M
    Autoimmun Rev; 2016 Oct; 15(10):983-93. PubMed ID: 27491568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A; Taylor RR; Mamotte CD
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
    Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
    Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
    Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
    Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.